House Set To Act on Bill that Could Result in Higher Medicaid Rebates and 340B Discounts

The U.S. House Energy and Commerce Committee is scheduled to mark up COVID-19 relief legislation today with language that could cause pharmaceutical manufacturers to owe states Medicaid drug rebates worth more than a drug’s average manufacturer price (AMP).

The language is in the Medicaid subtitle of the Democratic-controlled E&C committee’s draft pandemic relief bill. Last week, House and Senate Democrats passed budget reconciliation bills, with the goal of tucking Democratic-approved COVID-19 relief in the final version and getting it passed by the Senate on a simple majority vote, rather than by filibuster-proof 60-vote supermajority. The E&C panel and other House committees are writing and voting on the parts of the relief bill under their jurisdictions. House Speaker Nancy Pelosi (D-Calif.) said last week she hoped to send the House bill to the Senate by the end of this month.

The U.S. House Energy and Commerce Committee is scheduled to mark up COVID-19 relief legislation today with language that could cause pharmaceutical manufacturers to owe states Medicaid drug rebates worth more than a drug’s average manufacturer price (AMP).

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report